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Abstract
Background: During the past three decades conflicting evidences have been published on the use of non-invasive
ventilation (NIV) in patients with acute cardiogenic pulmonary edema (ACPE). The aim of this study is to describe
the management of acute respiratory failure (ARF) due to ACPE in twelve Italian emergency departments (EDs). We
evaluated prevalence, characteristics and outcomes of ACPE patients treated with oxygen therapy, continuous
positive airway pressure (CPAP) or Bi-level positive airway pressure (BiPAP) on admission to the EDs.
Methods: In this multicenter, prospective, observational study, consecutive adult patients with ACPE were enrolled
in 12 EDs in Italy from May 2009 to December 2013. Three study groups were identified according to the initial
respiratory treatment: patients receiving oxygen therapy, those treated with CPAP and those treated with BiPAP.
Treatment failure was evaluated as study outcome.
Results: We enrolled 1293 patients with acute cardiogenic pulmonary edema. 273 (21%) began with oxygen, 788 (61%)
with CPAP and 232 (18%) with BiPAP. One out of four patient who began with oxygen was subsequently switched to NIV
and initial treatment with oxygen therapy had an odds ratio for treatment failure of 3.65 (95% CI: 2.55–5.23, p < 0.001).
Conclusions: NIV seems to be the first choice for treatment of ARF due to ACPE, showing high clinical effectiveness and
representing a rescue option for patients not improving with conventional oxygen therapy.
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Background
Acute cardiogenic pulmonary edema (ACPE) represents
a heterogeneous [1–3] syndrome with a mortality rate
up to 9.5% [4]. Although many clinical trials by the end
of ‘90s showed that noninvasive ventilation (NIV) de-
creases the need for intubation and mortality in ACPE
[5], a study by Gray and colleagues cast doubt on previ-
ous published data [6]. From one hand, medical therapy
of ACPE is well defined in clinical practice, following
strong recommendations suggested by international
guidelines on the use of diuretics, opiates, vasodilators,
vasopressors and thromboembolism prophylaxis [4]. On
the other hand, treatment of acute respiratory failure
(ARF), beyond oxygen administration, remains a ques-
tion of controversy. Most of the recent guidelines do not
provide a strong recommendation on the use of NIV to
treat ARF due to ACPE [4, 7–10]. In view of the absence
of a strong recommendation on the use of continuous
positive airway pressure (CPAP) or bi-level positive air-
way pressure (BiPAP) to treat ARF due to ACPE, an
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evaluation on the use of both techniques in daily clinical
practice is needed. The aim of this study is to describe
the management of ARF due to ACPE in twelve Italian
emergency departments. We evaluated prevalence, char-
acteristics and outcomes of ACPE patients treated with
oxygen therapy, CPAP or BiPAP on admission according
to attending physicians judgement.
Methods
This was a multicenter, prospective, observational study
on consecutive adult patients admitted with diagnosis of
ACPE to 12 EDs in Italy from May 2009 to December
2013, see Appendix. The Institutional Review Boards of
all the hospitals approved the study, while the informed
consent was waived due to the observational nature of
the study. ACPE was defined by the presence of all the
following: acute-onset dyspnea, widespread pulmonary
rales and pulmonary congestion on chest X-ray (CXR),
plus at least one among: 1) respiratory distress; 2) respira-
tory rate ≥ 30 breath/minute; 3) pH < 7.35 and partial
pressure of carbon dioxide on arterial blood > 45mmHg
in Venturi Mask with an inspiratory fraction of oxygen of
0.50 (flow of 12 L/min). Patients who required an immedi-
ate endotracheal intubation or other life-saving interven-
tions were excluded from the study. Data recorded on
admission to the EDs included demographics, comorbidi-
ties, clinical and instrumental data (vital signs, arterial
blood gas analysis, blood chemistry, electrocardiogram,
CXR), medical therapy, respiratory support and complica-
tions. All data were collected on an electronic case report
form and anonymously stored in a centralized database
(www.acpe.it). Three study groups were identified accord-
ing to the initial respiratory treatment: patients receiving
oxygen therapy, those treated with CPAP and those
treated with BiPAP. All the options were available in the
twelve participating centers and the decision to initiate
oxygen, CPAP or BiPAP was taken by the attending physi-
cians, based on their personal judgement and local atti-
tude. The primary study outcome was treatment failure
defined as at least one of the following: 1) discontinuation
of the technique (either oxygen or CPAP or BiPAP) after
one hour from its initiation for a.
deterioration of either gas exchange or clinical status;
2) death. All statistical analyses were run using SPSS®,
version 20, for MAC platform. Continuous data were
presented as median values with interquartile range
(IQR) of the 25th and 75th percentiles. Categorical data
were presented as absolute number and percentage. Ac-
cording to previous literature, the sample size calcula-
tion was based on an assumed rate of treatment failure
of 25% in the oxygen therapy group and of 15% in the
group of patients treated with either CPAP or BiPAP. If
these assumptions were correct, a minimum of 500 pa-
tients would be enrolled to detect such a reduction with
a power of 90% and a two-sided type 1 error rate of 5%.
Data among groups were compared using a Mann-Whitney
or Kruskal-Wallis tests if continuous, and a chi-squared test
or Fisher exact test if categorical. A p-value of < 0.05 was
considered statistically significant.
Results
A total of 1300 patients were enrolled in the study. 7 pa-
tients were excluded due to their immediate intubation.
Demographics, comorbidities and data on hospital ad-
mission of the final population of 1293 patients (median
age: 81 years, 51% males) are reported in Table 1. The
five most frequent causes of ACPE included hypertensive
crisis (22%), acute coronary syndrome (19%), cardiac
arrhythmia (8%), low respiratory tract infections (8%),
valvular disease or ruptured mitralic chordae (3%).
ARF was treated as follows: oxygen therapy for 273 pa-
tients (21%), CPAP for 788 (61%) and BiPAP for 232
(18%), see Fig. 1. Among patients who were treated with
either CPAP or BiPAP anytime during the
hospitalization the following complications were de-
tected: pneumothorax in one patient, vomiting in 15 pa-
tients and shock in 25 patients.
A total of 112 patients (9%) died during hospitalization, in-
cluding 28 patients (10%) in the oxygen group, 61 (8%) in
the CPAP group and 23 (10%) in the BiPAP group, p= 0.330,
see Fig. 1. Early mortality (within 24 h of admission from the
ED) was 3% (38 patients): 9 patients (3%) in the oxygen
group, 21 (3%) in the CPAP group and 8 (3%) in the BiPAP
group, p= 0.760. A total of 29 patients (2%) underwent endo-
tracheal intubation (ETI) in the entire study population: 2
(1%) in the oxygen group, 13 (2%) in the CPAP group, and
14 (6%) in the BiPAP group, p < 0.05. Treatment failure was
experienced by 85 patients (31%) in the oxygen group, 98
(12%) in the CPAP group and 34 (15%) in the BiPAP group,
p < 0.05. A total of 66 patients out of 273 (24%) who began
with oxygen were subsequently switched to NIV. Median
length of stay was 9 days (IQR 5–13) in the entire study
population and no significant differences were detected
among the three study groups, p= 0.533. After adjustment
for several confounders (including arterial pH, PaO2/FiO2 ra-
tio, sex, age, systolic blood pressure, confusion on admission
and nitrate use), an initial treatment with oxygen therapy
showed an odds ratio for treatment failure of 3.65 (95% CI:
2.55–5.23, p < 0.001), see Fig. 2.
Discussion
Our study shows that physicians apply NIV in almost
80% of patients presenting to the ED with ACPE. Not-
ably, one out of four patients who were initially treated
with oxygen therapy were switched to NIV. We show
that an initial treatment with oxygen therapy is associ-
ated with more than 3 fold risk of treatment failure dur-
ing hospitalization.
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So far, no real life studies evaluated the use of NIV in
patients with ACPE. The EFICA study enrolled 599 pa-
tients with acute decompensated heart failure (ADHF)
and among them 82% had ACPE treated in intensive
care unit, showing a total mortality of 27% at 4 weeks
[1]. Previous data on mortality have been published
mainly from either registries or surveys enrolling pa-
tients with ADHF, ACPE, heart failure plus hypertension,
right heart failure and cardiogenic shock [2, 3]. We ex-
cluded 7 patients who were intubated on admission to
Table 1 Demographics, comorbidities, clinical and laboratory data on hospital admission of the study population, according to the
three study groups
Study population Oxygen Group n = 273 CPAP Group n = 788 BiPAP Group n = 232 p+ p# p§
n. (%) 1293 (100) 273 (100) 788 (100) 232 (100)
Demographics, n.(%)
Age, median (IQR) years 81 (73–86) 80 (73–85) 81 (73–86) 80 (74–86) 0.366 0.828 0.369
Female sex 635 (49) 137 (50) 389 (49) 107 (46) 0.548 0.385 0.648
Comorbidities, n(%)
COPD 406 (31) 92 (34) 241 (31) 72 (32) 0.633 0.798 0.357
Diabetes 495 (38) 112 (41) 292 (37) 91 (39) 0.482 0.549 0.294
Chronic kidney disease 353 (27) 87 (32) 215 (27) 51 (22) 0.046 0.106 0.057
Hypertension 974 (75) 198 (72) 594 (75) 182 (78) 0.306 0.336 0.227
Atrial fibrillation 264 (20) 64 (23) 154 (20) 46 (20) 0.376 0.924 0.163
Congestive heart failure 315 (24) 67 (24) 178 (23) 70 (30) 0.061 0.018 0.938
Coronary artery disease 599 (46) 134 (49) 360 (46) 105 (45) 0.585 0.909 0.304
Valvulopaty 300 (23) 69 (25) 193 (24) 38 (16) 0.024 0.009 0.361
ACPE in the previous 12months 295 (23) 63 (23) 178 (23) 54 (23) 0.970 0.826 0.908
Data on admission, n.(%)
Systolic blood pressure, median (IQR)
mmHg
160 (140–190) 159 (135–180) 164 (140–190) 162 (140–185) 0.043 0.900 0.012
Diastolic blood pressure, median (IQR)
mmHg
90 (80–105) 90 (75–100) 95 (80–107) 87 (75–100) 0.000 0.001 0.025
Mean blood pressure, median (IQR)
mmHg
115 (98–131) 113 (95–127) 117 (99–133) 113 (98–127) 0.084 0.217 0.064
Hypotension* 19 (1) 4 (1) 14 (2) 1 (< 1) 0.321 0.132 0.992
Heart rate, median (IQR) beats/min 104 (90–120) 100 (86–113) 108 (95–120) 102 (92–120) 0.000 0.102 0.000
Respiratory rate, median (IQR)
breaths/min
34 (30–40) 30 (26–36) 35 (30–40) 35 (30–40) 0.000 0.824 0.000
Respiratory rate ε breaths/min, n. (%) 568 (49) 72 (29) 374 (55) 122 (53) 0.000 0.620 0.000
pH, median (IQR) 7.29 (7.20–7.37) 7.37 (7.28–7.42) 7.28 (7.20–7.35) 7.23 (7.13–7.31) 0.000 0.000 0.000
pH < 7.35, n. (%) 862 (69) 115 (44) 550 (72) 197 (87) 0.000 0.000 0.000
PaCO2, median (IQR) mmHg 47 (38–59) 42 (35–51) 47 (39–57) 60 (45–72) 0.000 0.000 0.000
PaCO2≤ 35 mmHg, n. (%) 235 (18) 74 (27) 136 (17) 25 (11) 0.000 0.012 0.000
PaCO2≥ 45 mmHg, n. (%) 732 (58) 116 (43) 440 (57) 176 (76) 0.000 0.000 0.000
PaO2/FiO2 ratio, median (IQR) 195 (134–247) 209 (155–252) 190 (128–248) 181 (136–243) 0.119 0.623 0.056
PaO2/FiO2 ratio < 200, n. (%) 652 (51) 116 (43) 412 (54) 124 (54) 0.006 0.992 0.001
HCO3
−, median (IQR) mmol/L 22 (20–26) 23 (20–26) 22 (19–25) 23 (20–26) 0.004 0.042 0.009
HCO3
− > 24mEq/L 415 (33) 104 (38) 226 (30) 85 (37) 0.011 0.045 0.025
Lactates, median (IQR) mmol/L 2.2 (1.3–3.9) 2 (1.1–3.1) 2.3 (1.4–4) 2.25 (1.2–4) 0.070 0.573 0.026
Kelly scale > 3 61 (5) 10 (4) 27 (3) 24 (11) 0.000 0.000 0.452
Footnotes: CPAP continuous positive airway pressure, BiPAP Bi-level Positive Airway Pressure, IQR 25–75 interquartile range, COPD chronic obstructive pulmonary
disease, ACPE acute cardiogenic pulmonary edema, PaO2 partial pressure of oxygen in the arterial blood, FiO2 inspiratory fraction of oxygen, PaCO2 partial pressure
of carbon dioxide in the arterial blood, HCO3
− bicarbonates, *Hypothension was defined as systolic blood pressure < 90 mmHg; +among the three groups;
#between CPAP Group vs. BiPAP Group; §between Oxygen Group vs. CPAP plus BiPAP Groups
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the ED and we reported in-hospital mortality for pa-
tients with ACPE of 9%. Our mortality rate is in line
with that published by both the EHFS2 study group and
Gray and coworkers [3, 6].
Our study points out a diffuse perception among phy-
sicians that NIV is more beneficial than oxygen to man-
age ARF in ACPE patients. We found that emergency
physicians apply in clinical practice either CPAP or
BiPAP in almost 80% of ACPE patients and the vast ma-
jority of them are initially treated with CPAP. These data
are interesting in light of the heterogeneity of the rec-
ommendations suggested by international societies and
findings published by Grey and coworkers [3, 8, 9]. Fur-
thermore, the fact that in our study 21% of ACPE pa-
tients were treated with standard oxygen therapy seems
even more interesting; this choice could be attributed to
personal or local attitude and surely it is partially justi-
fied by a less severe presentation of these patients;
nevertheless, the switch to NIV of one out of four pa-
tients seems to suggest an initial under-treatment des-
pite many guidelines does not recommend NIV so
firmly. In line with our results, the last ERS/ATS guide-
lines recommend NIV for ARF due to ACPE more
strongly (10). Finally, our results are of special interest
in view of the limited use of NIV in the emergency room
as recently pointed out [11]. One possible explanation of
the large use of NIV/CPAP in our study may be found
in the high severity of the disease on admission, since
two thirds of our patients were acidotic on admission.
According to our results, emergency physicians seem to
be more willing to use NIV in case of high respiratory
rate, low pH and high level of PaCO2. Furthermore,
main drivers for choosing BiPAP (in comparison to
CPAP) were a Kelly score greater than 3, a low pH and a
high PaCO2. Due to its prospective nature, our study
lacks strict criteria to initiate oxygen, CPAP or BiPAP,
Fig. 1 Flow chart of the study population. Pts. = patients; CPAP = continuous positive airway pressure; BiPAP: Bi-level Positive Airway Pressure;
ETI = endotracheal intubation
Fig. 2 Independent predictors for clinical failure in the study population. OR: Odds ratio; CI: confidence intervals; PaO2: partial pressure of oxygen
in the arterial blood; FiO2: inspiratory fraction of oxygen; no nitrates: group of patients that were not treated with nitrates
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nevertheless we aimed to describe the real life manage-
ment of ARF in the Italians EDs. Only a randomized
controlled trial without crossover between groups could
detect a potential difference in mortality between oxygen
and NIV, but we think that the rate of switch from oxygen
to NIV in our study should lead physicians to monitor
more carefully ACPE patients treated with oxygen ther-
apy. Other limitations of our study are that we were not
able to evaluate medium and long-term outcomes and the
following episodes of ACPE and re-hospitalizations. This
study is strengthened by the multicentric and real life de-
sign, enrolling consecutive patients affected by ACPE (ac-
cording to a strict definition) and specifically focused on
NIV. A large RCT comparing these three methods is
needed and we suggest clinical failure being the primary
endpoint without patients’ crossover among groups. In
conclusion, NIV seems to be the first choice for treatment
of ARF due to ACPE, showing high clinical effectiveness
and representing a rescue option for patients not improv-
ing on conventional oxygen therapy.
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